Literature DB >> 3723403

Mechanisms of cell association of chloroquine to leucocytes.

M Raghoebar, P A Peeters, W B van den Berg, C A van Ginneken.   

Abstract

One approach currently being used to get more insight into the molecular mechanisms of action of drugs and their (micro)pharmacokinetic events is to perform cellular association studies. We have examined the association of the antimalarial and antirheumatic drug chloroquine (CQ) to isolated human blood cells. This study dealt with the hypothesis that inflammatory cells such as the leucocytes are the mediators of the anti-inflammatory activity of drugs, both as target cells and as potential vehicles for the transport of drugs to inflamed tissues. A suitable ligand-binding assay was developed to measure the cellular association of CQ. The polymorphonuclear leucocytes (PMNs) accumulated CQ to a greater extent than mononuclear leucocytes and red blood cells; this can be explained by the presence of a lot of acidic cellular organelles as lysosomes in the PMS, which trap the weak base CQ. The accumulation in the PMNs was dependent on temperature, cellular intactness and the extracellular pH. The apparent temperature dependency indicates that one or more energy delivery steps are involved in the entire process of cellular association. Scatchard analysis of the association of CQ to human PMNs revealed two different sites, with KD values of 1.7 microM and 0.12 mM for the low and high affinity site, respectively. The cellular association of CQ is inhibited by supratherapeutic concentrations of some nonsteroidal anti-inflammatory drugs. This is possibly due to an interaction at the level of the cellular transport pathways and emphasizes the value of micropharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3723403

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Differential uptake of chloroquine by human keratinocytes and melanocytes in culture.

Authors:  G Sjölin-Forsberg; B Berne; M Johansson; M J Olsson; O Rollman
Journal:  Arch Dermatol Res       Date:  1996-04       Impact factor: 3.017

2.  Chloroquine interaction with inflammatory human polymorphonuclear leucocytes.

Authors:  M Raghoebar; J A Huisman; W B van den Berg; P L van Riel; C A van Ginneken
Journal:  Agents Actions       Date:  1988-07

3.  Regulation of the Cinnamate 4-Hydroxylase (CYP73A1) in Jerusalem Artichoke Tubers in Response to Wounding and Chemical Treatments.

Authors:  Y. Batard; M. Schalk; M. A. Pierrel; A. Zimmerlin; F. Durst; D. Werck-Reichhart
Journal:  Plant Physiol       Date:  1997-03       Impact factor: 8.340

4.  The cellular association of sodium salicylate and indomethacin in peritoneal fluid of ascites bearing mice.

Authors:  M Raghoebar; W B van den Berg; J A Huisman; C A van Ginneken
Journal:  Agents Actions       Date:  1987-12

5.  Bioavailability of hydroxychloroquine tablets in healthy volunteers.

Authors:  S E Tett; D J Cutler; R O Day; K F Brown
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

6.  Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria.

Authors:  P A Peeters; K de Leest; W M Eling; D J Crommelin
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

7.  Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial.

Authors:  Caio B Zanetti; Tatiana Pedrosa; Léonard de V K Kupa; Nadia E Aikawa; Eduardo F Borba; Margarete B G Vendramini; Clovis A Silva; Sandra G Pasoto; Eloisa Bonfa
Journal:  Clin Rheumatol       Date:  2021-01-24       Impact factor: 2.980

Review 8.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.